The influence of sarcopenia on survival and surgical complications in ovarian cancer patients undergoing primary debulking surgery

Publication date: Available online 19 January 2017
Source:European Journal of Surgical Oncology (EJSO)
Author(s): Iris J.G. Rutten, Jorne Ubachs, Roy F.P.M. Kruitwagen, David P.J. van Dijk, Regina G.H. Beets-Tan, Leon F.A.G. Massuger, Steven W.M. Olde Damink, Toon Van Gorp
BackgroundSarcopenia, severe skeletal muscle loss, has been identified as a prognostic factor in various malignancies. This study aims to investigate whether sarcopenia is associated with overall survival (OS) and surgical complications in patients with advanced ovarian cancer undergoing primary debulking surgery (PDS).MethodsOvarian cancer patients (n=216) treated with PDS were enrolled retrospectively. Total skeletal muscle surface area was measured on axial computed tomography at the level of the third lumbar vertebra. Optimum stratification was used to find the optimal skeletal muscle index cut-off to define sarcopenia (≤38.73 cm²/m²). Cox-regression and Kaplan-Meier analysis were used to analyse the relationship between sarcopenia and OS. The effect of sarcopenia on the development of major surgical complications was studied with logistic regression.ResultsKaplan-Meier analysis showed a significant survival disadvantage for patients with sarcopenia compared to patients without sarcopenia (p=0.010). Sarcopenia univariably predicted OS (HR 1.536 (95%CI 1.105-2.134), p=0.011) but was not significant in multivariable Cox-regression analysis (HR 1.362 (95%CI 0.968-1.916) p=0.076). Significant predictors for OS in multivariable Cox-regression analysis were complete PDS, treatment in a specialised centre and the development of major complications. Sarcopenia was not predictive of major complications.ConclusionSarcopenia was not predictive of OS or major complications in ovarian cancer patients undergoing primary debulking surgery. However a strong trend towards a survival disadvantage for patients with sarcopenia was seen. Future prospective studies should focus on interventions to prevent or reverse sarcopenia and possibly increase ovarian cancer survival. Complete cytoreduction remains the strongest predictor of ovarian cancer survival.



http://ift.tt/2k94ToV